Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients
Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients
复制标题
DOI：
10.1007/s00592-013-0489-3
复制
发表时间：
2013-12-01
影响因子：
3.8
通讯作者：
Avogaro, Angelo
中科院分区：
文献类型：
--
作者：
Fadini, Gian Paolo;Simioni, Natalino;Avogaro, Angelo
GLP-1受体激动剂利拉鲁肽可有效降低2型糖尿病（T2 D）患者的HbA 1c。此外，利拉鲁肽治疗与显著体重减轻相关。在本研究中，我们在2型糖尿病门诊患者人群中分析了利拉鲁肽治疗的血糖和体重效应之间的相互关系。入组并随访了自2010年9月至2012年7月在3家门诊开始利拉鲁肽治疗的T2 D患者。我们收集了人体测量数据、心血管危险因素、糖尿病病程、并发症患病率和抗糖尿病药物史等基线信息。我们在基线时和每4个月收集一次HbA 1c和体重。共纳入166例患者，平均年龄为56.6 +/- A 8.9（平均值+/- A SD）岁，基线HbA 1c为8.7 +/- A 1.3%，BMI为36.3 +/- A 6.4 kg/m2。平均随访时间为9.4 +/- A 4.2个月（范围4-16）。患者平均降低1.5 +/- A 1.3% HbA 1c和4.0 +/- A 5.0 kg体重。大多数患者（73.5%）HbA 1c改善，体重减轻。HbA 1c下降的重要独立决定因素是基线HbA 1c（r = 0.673; p < 0.001）和既往胰岛素治疗（r = -0.251; p < 0.001）。体重减轻的唯一独立决定因素是基线BMI（r = 0.429; p < 0.001）。HbA 1c下降与基线BMI或体重减轻无关。体重减轻与基线HbA 1c或HbA 1c下降无关。在真实环境中，T2 D患者接受利拉鲁肽治疗后获得的血糖改善和体重减轻是独立的，可能由不同机制介导。
The GLP-1 receptor agonist Liraglutide is effective in reducing HbA1c in type 2 diabetic (T2D) patients. In addition, treatment with Liraglutide is associated with significant weight loss. In this study, we analyzed the inter-relationships between glycemic and weight effects of Liraglutide treatment in a population of type 2 diabetic outpatients. T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up. We collected baseline information about anthropometric data, cardiovascular risk factors, diabetes duration, prevalence of complications and history of anti-diabetic medications. We collected HbA1c and body weight at baseline and every 4 months. A total of 166 patients were included, who were on average 56.6 +/- A 8.9 (mean +/- A SD) years old and had a baseline HbA1c of 8.7 +/- A 1.3 % and BMI 36.3 +/- A 6.4 kg/m(2). Mean follow-up was 9.4 +/- A 4.2 months (range 4-16). Patients lost on average 1.5 +/- A 1.3 % HbA1c and 4.0 +/- A 5.0 kg body weight. Most patients (73.5 %) improved HbA1c and loosed weight. Significant independent determinants of HbA1c drop were baseline HbA1c (r = 0.673; p < 0.001) and previous insulin therapy (r = -0.251; p < 0.001). The only independent determinant of weight loss was baseline BMI (r = 0.429; p < 0.001). Drop in HbA1c was unrelated to baseline BMI or weight loss. Weight loss was unrelated to baseline HbA1c or drop in HbA1c. Glycemic improvement and weight reduction obtained with Liraglutide treatment in T2D patients in a real-world setting are independent and possibly mediated by different mechanisms.